China Health Group Limited (Stock Code: 673) has announced several significant changes to its Board of Directors and committees, effective 31 October 2025. According to the announcement, Mr. Cao Xu has been appointed as an executive director, chairman of the Board, and chairman of the Nomination Committee. He has approximately 14 years of investment experience and four years in the pharmaceutical industry.

In addition, the company has named Ms. Ying Rensi as an executive director. She is currently the general manager and executive director of a medical equipment distribution firm in mainland China, as well as chief executive officer of a multimedia design agency in the United States. Her background includes a master’s degree in Architecture and experience overseeing strategic operations.

The announcement also covers the appointment of Mr. Ying Wei as a non-executive director and a member of both the Nomination Committee and Remuneration Committee. He has a Master’s Degree in Business Administration and a Bachelor’s Degree in Economics, along with non-practising membership in the Chinese Institute of Certified Public Accountants.

Further changes include the appointment of two independent non-executive directors, Mr. Wu Hui and Mr. Li Hongyi. Mr. Wu, who has extensive teaching and research experience in finance and accounting, will serve as chairman of the Audit Committee as well as a member of the Nomination and Remuneration Committees. Mr. Li brings medical expertise, currently serving as a chief physician in the cardiovascular department of a Beijing hospital. He will become a member of the Audit, Nomination, and Remuneration Committees.

The chairmanship of the Remuneration Committee moves to existing independent non-executive director, Ms. Yang Huimin. She has a background in economics, management, and finance, alongside experience in listed-company operations.

Regarding resignations, the announcement notes that Mr. Zhang Fan has stepped down as executive director, chairman of the Board, and chairman of the Nomination Committee. Mr. Xing Yong (formerly executive director), Mr. Wang Jingming (formerly non-executive director), along with three independent non-executive directors – Mr. Jiang Xuejun, Mr. Du Yanhua, and Mr. Lai Liangquan – have also tendered their resignations. Each individual has cited personal business commitments, and all have confirmed there is no disagreement with the company’s Board.

Following these changes, the new Board consists of executive directors, non-executive directors, and independent non-executive directors, each subject to relevant rotation and re-election requirements. The announcement emphasizes that these appointments and resignations aim to align leadership and strategic oversight with the organization’s evolving needs.